Precision Medicine
Advancing the paradigm shift to genomic-guided treatments
Value-based care, the paradigm shifts to genomic-guided treatments, increasing patient volumes, and workforce challenges are driving the need to provide community oncologists with innovative processes and tools to facilitate effective care delivery. Dr. Patel has started multiple research initiatives that addresses these critical issues while analyzing current gaps in utilizing precision medicine in community oncology.By enabling access, education, and support for science-led precision care solutions in disadvantaged communities, Dr. Patel is developing a deeper understanding of complex genomic landscapes in historically underrepresented populations and ensure diversity, inclusion, and access in cancer research. He designed REPRESENT study. The REPRESENT study will generate one of the most comprehensive repositories of clinical-genomic information available as a result of the range of molecular profiling techniques, clinical data, and diverse racial backgrounds involved. Alsoby incorporating information on social determinants of health into our dataset, we have the opportunity to better understand the role of social support, education, housing, and other socioeconomic factors in contributing to cancer outcomes.
Speaking engagement on 
Publications on Valued-based Speaking
-
Dr Kashyap Patel Updates on Exciting Developments at ASCO22
Jun 02, 2022 - AJMC
-
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study
May 16, 2022 - Targeted Oncology
-
Differentiating Pseudoprogression From Hyperprogression in Patients Treated With Immunotherapies
Feb 14, 2022 - Targeted Oncology
-
MRD and Value-Based Care Models
Feb 04, 2022 - Targeted Oncology
-
Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice
Sep, 2022 - Science Direct
Publications
-
Patel K, Clinton N et al COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care, Targeted Oncology, March 20
-
Patel K, Clinton N, Next-Generation Sequencing Can Improve Treatment Decisions, But Community Uptake Remains Delayed, Targeted Oncology, September 2019
-
Gregory J Tsongalis…… Kashyap Patel; Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Colorectal Cancer. Am J Clin Pathol 2020 Jul 7;154(2):266-276. 10.1093/ajcp/aqaa044.
-
Patel K et al. The Role of Precision Medicine in Lung Cancer: Case Study and Review of Literature. Acta Scientific CANCER BIOLOGY (ISSN: 2582-4473); Volume 5 Issue 11 November 2021
-
Patel K et al. Differentiating PseudoprogressionFromHyperprogression in Patients Treated With Immunotherapies. Targeted Therapies in Oncology, February 2, 2022, Volume 11, Issue 3
-
Patel K et al. The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community Oncology. Targeted Therapies in Oncology, May 2021, Volume 10, Issue 7
-
Patel K et al. Despite Advances in Precision Medicine, Disparities Persist. Targeted Therapies in Oncology, November 2 2020, Volume 9, Issue 16
-
Patel K et al. COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care. Targeted Therapies in Oncology, May 1 2020, Volume 9, Issue 5
-
Patel K et al. PRECISION MEDICINE; A PINNACLE OF INNOVATION OR A PITFALL OF IMPLICIT AND EXPLICIT BIASES? Oncolytics Today. Spring 2022 Page 56-50
-
Patel K et al Clinical utility of widespread germline testing of cancer patients in a diverse community cancer clinic (ASCO 2022-e e18537)
-
Patel K. COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care, Targeted Oncology March 30, 2020
-
Clinton N, Patel K, Widener S. The impact of a precision medicine program on molecular testing rates for advanced non-small cell lung cancer (aNSCLC): Based on community-based provider survey assessment 2020 May: 38: 15: e 19179
-
Patel K et al. Social determinants of health in a prospective study of whole-exome sequencing in advanced cancer patients from underserved communities. ASCO 2022; e18539
-
Gor A, Patel K et al. The role of real-world evidence (RWE) registries using NGS testing to address cancer health disparities (CHD) in small community oncology practices. ASCO 2022; e18519 Publication
-
Brufsky A….. Patel Kashyap et al Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET). Presented at the ASCO 2022.
-
Patel K et al. Clinical utility of widespread germline testing of cancer patients in a diverse community cancer clinic. J Clin Oncol 40, 2022 (suppl 16; abstr e18537)
-
Patel K at al. The Role of Precision Medicine in Lung Cancer: Case Study and Review of Literature. Presented at the NCODA.
-
Patel K et al. A Treatment Journey to Remission: A Case Report of a Cholangiocarcinoma Patient Treated with Surgery, Adjuvant and Palliative
-
A Treatment Journey to Remission: A Case Report of a Cholangiocarcinoma Patient Treated with Surgery, Adjuvant and Palliative Chemotherapy, Orthotopic Liver Transplantation, Radiotherapy; A Journey from Despair to Hope
-
Carolina Blood and Cancer Care Associates' Patient-Centered Transformation
-
Patel K et al. Multi-locus Inherited Neoplasia Alleles Syndrome (MINAS) with Birt-Hogg-Dube Syndrome (BHG) and Li-Fraumeni Syndrome (LFS): Case Report.
-
Patel K et al. Leptomeningeal Involvement in CLL Treated with Ibrutinib: Case Study and Literature Review.
-
Patel K et al. Precision Medicine: A Pinnacle of Innovation or a Pitfall of Explicit and Implicit Biases?
-
Patel K et al. The Role of Precision Medicine in Lung Cancer: Case Study and Review of Literature.
